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1. Introduction 
Activation of the coagulation cascade leading to generation of thrombin has been 
extensively documented in various forms of lung injury including systemic sclerosis-
associated interstitial lung disease (SSc-ILD). The molecular mechanisms underlying the 
pathogenesis and progression of lung fibrosis in SSc-ILD and in idiopathic pulmonary 
fibrosis (IPF) are not entirely clear. The conceptual process of fibrogenesis involves tissue 
injury and activation of the coagulation cascade, the release of various fibrogenic factors, 
and the induction of myofibroblasts culminating in enhanced extracellular matrix 
deposition. Cells with a myofibroblast phenotype appear in the early stages of fibrosis and 
are characterized by an increased proliferative capacity and abundant expression of ǂ-SMA, 
collagens and other extracellular matrix proteins (Hinz et al., 2007). Myofibroblasts can be 
cultured from bronchoalveolar lavage (BAL) fluid of SSc-ILD patients, and thrombin activity 
is also significantly greater in BAL fluid from SSc-ILD patients compared with healthy 
controls (Ludwicka et al., 1992; Ohba et al., 1994). Thrombin differentiates lung fibroblasts to 
a myofibroblast phenotype, increases lung fibroblast proliferation (Bogatkevich et al., 2001), 
and enhances the proliferative effect of fibrinogen on fibroblasts (Gray et al., 1993). 
Thrombin is also a potent inducer of fibrogenic cytokines, such as transforming growth 
factor-ǃ (TGF-ǃ) (Bachhuber et al., 1997), connective tissue growth factor (CTGF) (Chambers 
et al., 2000; Bogatkevich et al., 2006), platelet-derived growth factor-AA (PDGF-AA) (Ohba 
et al., 1994), chemokines (Mercer et al., 2007), and ECM proteins such as collagen, 
fibronectin, and tenascin in various cells, including lung fibroblasts (Tourkina et al., 2001; 
Chambers et al., 1998; Armstrong et al., 1996). 
Dabigatran is a selective direct thrombin inhibitor that reversibly binds to thrombin and 
prevents the cleavage of Arg-Gly bonds of fibrinogen needed for the formation of fibrin. 
Recently, we have demonstrated that binding of dabigatran to thrombin prevents cleavage 
of the extracellular N-terminal domain of the protease-activated receptor 1 (PAR-1), which is 
responsible for most profibrotic events induced by thrombin (Bogatkevich et al., 2009). In 
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the absence of dabigatran, thrombin binds to PAR-1, cleaves the peptide bond between 
residues Arg-41 and Ser-42, thereby unmasking a new amino terminus, SFLLRN, which 
then can bind to the second extracellular loop of PAR-1 and initiate receptor signaling 
(Macfarlane et al., 2001). Dabigatran-bound thrombin is unable to cleave and activate 
PAR-1. The aim of this chapter is to provide a molecular basis for therapeutic interventions 
in SSc-ILD by inhibition of thrombin. 
2. Increased expression of thrombin and PAR-1 in SSc-ILD 
Thrombin is a multi-functional serine protease and a key enzyme of blood coagulation, 
catalyzing the conversion of fibrinogen to fibrin. In addition to its essential role in 
coagulation, thrombin has several important functions at a cellular level, both in normal 
health and in multiple disease processes, including pulmonary fibrosis (Chambers, 2008). 
Our laboratory as well as others has demonstrated dramatically increased levels of thrombin 
in BALF from scleroderma patients with lung fibrosis and other fibrosing lung diseases 
(Ohba et al., 1994; Hernadez-Rodriguez et al., 1995). We have reported that BALF from 
normal subjects contains a low level of thrombin activity ranging from zero to 150 units per 
mg of BALF protein (48.6 ± 8.7 U/mg, mean ± SEM). BAL fluids of SSc patients express up 
to 100-fold higher thrombin activity, ranging from 22 to 7,525 units per mg of BALF protein 
(699.9 ± 201.1 U/mg, mean ± SEM; P < 0.001) (Fig. 1A). Elevated levels of thrombin activity 
have been also observed in bleomycin-induced pulmonary fibrosis in mice (Howell et al., 
2005). We found that the level of active thrombin in BAL fluid from bleomycin-treated mice 
was 35-fold higher (1.3 ± 0.1 ng/ml, mean ± SEM) compared to that in control mice treated 
with saline (46.1 ± 7.9 ng/ml, mean ± SEM; P < 0.01) (Fig. 1B). 
 
 
Fig. 1. (A) Thrombin levels in BALF of scleroderma patients (SSc, closed triangles, n = 42) 
and normal subjects (Nml, closed circles, n = 27). Active thrombin was measured by 
fluorometric method using a synthetic substrate Boc-Val-Pro-Arg-7-(4-methyl) 
coumarylamide, and expressed as units per mg of BALF protein. (B) Thrombin levels in 
BALF of mice treated with saline (1) and with bleomycin-induced pulmonary fibrosis (2). 
0
20
40
60
1 2
Ac
tiv
e
 
Th
ro
m
bi
n,
 
n
g/
m
l *
B
0
Th
ro
m
bi
n 
Un
its
/m
g 
Pr
o
te
in
900
300
1500
5000
7000
SSc Nml
A
Ac
tiv
e
 
Th
ro
m
bi
n,
 
n
g/
m
l
Ac
tiv
e
 
Th
ro
m
bi
n,
 
n
g/
m
l
Th
ro
m
bi
n 
Un
its
/m
g 
Pr
o
te
in
Th
ro
m
bi
n 
Un
its
/m
g 
Pr
o
te
in
www.intechopen.com
Inhibition of Thrombin as a Novel Strategy in  
the Treatment of Scleroderma-Associated Interstitial Lung Disease 133 
 
Fig. 2. Mechanism of PAR-1 activation. Proteolytic cleavage of the N-terminus results in the 
unmasking of a tethered ligand SFLLRN, which in turn interacts with extracellular loop-2 of 
the receptor and initiates cell signaling via activation of heterotrimeric G-proteins. 
 
 
Fig. 3. PAR-1 and ǂ-SMA expression is significantly increased in pulmonary fibrosis 
associated with scleroderma. Sections of normal and scleroderma (SSc) lung stained by 
trichrome, ǂ-SMA antibody, and PAR-1 antibody; ǂ-SMA and PAR-1 were visualized as 
brown color by diaminobenzidine (DAB) and counterstained with hematoxilin. Top panel 
represents normal lung tissue, middle panel (SSc I) represents lung tissue in early stage of 
lung involvement and bottom panel (SSc II) represents lung tissue with late stage of fibrosis.  
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The majority of the cellular responses to thrombin are mediated via the G protein-coupled 
PAR-1 receptor (Howell et al., 2002; Coughlin 1999). PAR-1 is activated by proteolytic 
cleavage of N-terminal domains, leading to the exposure of a new amino-terminus, a 
“tethered ligand” that in turn activates the receptor (Fig. 2). PAR-1 activation has been 
shown to be an important in the pathophysiology of various lung diseases, including SSc-
ILD (Howell et al., 2002; Bogatkevich et al., 2005). PAR-1 is present in a variety of cell types, 
including leukocytes, platelets, T cells, endothelial cells, vascular smooth muscle cells and 
fibroblasts (Shrivastava et al., 2007). In the bleomycin model of pulmonary fibrosis, PAR-1 
deficient mice show a significant reduction of inflammatory cells in BALF as compared with 
wild-type mice, and significant protection from lung fibrosis is seen in the PAR-1 deficient 
mice (Howell et al., 2005). The relative protection from pulmonary fibrosis observed in this 
model is a reduction in expression of two major fibrogenic growth factors, CTGF and 
transforming growth factor ǃ- (TGF-ǃ), as well as a reduction of the chemokine (C-C motif) 
ligand 2 (CCL2)/monocyte chemotactic protein 1 (MCP-1). 
Elevated expression of PAR-1 has been shown in patients with IPF and in a murine model of 
bleomycin-induced lung fibrosis (Chambers, 2008; Howell et al., 2005). In previous studies 
we demonstrated that PAR-1 expression is also dramatically increased in lung tissue from 
scleroderma patients, mainly in lung parenchyma in context with myofibroblasts present in 
inflammatory and fibroproliferative foci (Bogatkevich et al., 2005). PAR-1 expression 
diminishes in the later stages of pulmonary fibrosis (Fig. 3) suggesting its important role in 
lung fibroblast activation during the early development of pulmonary fibrosis.  
3. SSc-ILD, thrombin, and myofibroblasts 
In the pathogenesis of pulmonary fibrosis in general and SSc-ILD in particular, lung 
fibroblasts undergo specific phenotypic modulation and develop cytoskeletal features 
similar to those of smooth muscle cells. These phenotypically altered, activated fibroblasts, 
or “myofibroblasts”, express a contractile isoform of actin (ǂ-smooth muscle actin, ǂ-SMA) 
and promote contractility of lung tissues. Myofibroblasts appear to be the principal 
mesenchymal cells responsible for tissue remodeling, collagen deposition, and the restrictive 
nature of the lung parenchyma associated with pulmonary fibrosis (Tomasek et al., 2002). 
We have demonstrated that myofibroblasts are present in the BALF of SSc patients and 
that myofibroblasts cultured from SSc BALF express more collagen I, III, and fibronectin 
than normal lung fibroblasts (Ludwicka et al., 1992). Myofibroblasts from BALF also show 
a greater proliferative response upon exposure to TGF-ǃ and PDGF when compared to 
normal lung fibroblasts. Several groups of investigators have demonstrated a correlation 
between fibrosis and ǂ-SMA expressing myofibroblasts in a number of different tissues 
(Tomasek et al., 2002; Zhang et al., 1994; Walker et al., 2001). Myofibroblasts isolated from 
various fibrotic tissues, including lungs, are thought to be the primary source of collagen 
and other ECM proteins (Tomasek et al., 2002; Zhang et al., 1994). Studies in animals 
employing the bleomycin-induced model of pulmonary fibrosis have identified 
myofibroblasts to be the primary source of increased collagen expression and a major 
source of cytokines and chemokines as well (Zhang et al., 1996; Vyalow et al., 1993). 
The precise source(s) of myofibroblasts is still not well known. Relative contributions from 
circulating mesenchymal stem cells or from local trans-differentiation of epithelial cells to 
fibroblasts have been reported (Hinz et al., 2007). It has become generally accepted that lung 
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fibroblasts may differentiate to a myofibroblast phenotype under the influence of local 
growth factors and cytokines, such as TGF-ǃ, endothelin-1, and thrombin (Hinz et al., 2007; 
Bogatkevich et al., 2001; Shi-Wen et al., 2004). Interestingly, thrombin itself has been 
demonstrated to induce the secretion of TGF-ǃ and endothelin-1 (Shi-Wen et al., 2004; 
Bachhuber et al., 1997). 
4. Thrombin induces differentiation of lung fibroblasts to a myofibroblast 
phenotype resistant to apoptosis while inducing apoptosis of alveolar 
epithelial cells 
Our previous studies demonstrated that thrombin differentiates normal lung fibroblasts 
to a myofibroblast phenotype via the PAR-1/PKCε-dependent pathway (Bogatkevich et 
al., 2001; 2003; 2005). We previously reported that thrombin induces resistance to FasL-
induced apoptosis in normal lung fibroblasts and that a similar level of resistance to FasL 
is observed in SSc lung fibroblasts de novo (Bogatkevich et al., 2005). Interestingly, we also 
found that thrombin-induced resistance to apoptosis is not specific only for FasL. We 
showed that thrombin also induces resistance to other apoptotic factors such as 
camptothecin and ceramide, and that SSc lung fibroblasts are also resistant to apoptosis 
induced by these stimuli. Because of the involvement of Fas-FasL pathway in various 
pulmonary disorders, we have selected this molecule for further investigations of 
apoptosis. We demonstrated that FasL induces apoptosis in normal lung fibroblasts in a 
dose-dependent manner and that this effect is inhibited by thrombin, as well as by 
overexpression of constitutively-activated PAR-1 or constitutively-activated PKCε 
(Bogatkevich et al., 2005).  
The activation of Akt in different cell lines is necessary for promotion of cell survival and 
protection from apoptosis. We observed that thrombin induced sustained phosphorylation 
of Akt at Ser-473 in lung fibroblasts. Phosphorylation of Akt occurred within 10 min of 
thrombin treatment, reaching a maximum at 30 min and decreasing after 2 hours (Fig. 4 A). 
Basal levels of total Akt were similar in lung fibroblasts and in A549 alveolar epithelial cells 
(AEC), and thrombin induced Akt phosphorylation only in lung fibroblasts and not in AEC 
(Fig.4B) at any time point. 
Activation of the thrombin receptor PAR-1 is known to mediate apoptosis of intestinal 
epithelial and lung epithelial cells (Suzuki et al, 2005; Ando et al., 2007). We incubated 
human A549 AEC and mouse primary AEC with thrombin to determine if thrombin induces 
apoptosis in these cells. After 24 hours of incubation with thrombin (1U/ml), A549 cells 
demonstrated 4.2 times and AT2 cells demonstrated 3.45 times more DNA fragments when 
compared to control cells, consistent with thrombin induction of apoptosis of these different 
AEC types (Fig. 4C). 
The best recognized hallmark of both early and late stages of apoptosis is the activation of 
cysteine aspartate-specific proteases, caspases. Upon activation, the caspases cleave specific 
substrates and thereby mediate many of the typical biochemical and morphological changes 
in apoptotic cells, such as cell shrinkage, chromatin condensation, DNA fragmentation and 
plasma membrane blebs (Kohler et al., 2002). Caspase-3 is activated during most apoptotic 
processes and is believed to be the main executioner caspase. We observed that thrombin 
activates caspase-3 in AEC, but not in lung fibroblasts (Fig. 4D) 
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Fig. 4. Distinct effects of thrombin in lung fibroblasts and AEC. (A) Time course of 
thrombin-induced Akt Phosphorylation was determined in lung fibroblasts treated with 
1U/ml thrombin for various time points. (B) AEC (lanes 1 and 2) and lung fibroblasts (lanes 
3 and 4) were incubated with or without thrombin for 30 minutes. Cell extracts were 
immunoblotted with phospho-Akt or total Akt antibody (Cell Signaling Technology). (C) 
Thrombin-induced apoptosis of human SAEC and mice AT2 cells. Each bar represents the 
mean ± SD of duplicate determinations in 3 experiments. *Statistically significant differences 
between cells stimulated with thrombin and dabigatran versus cells stimulated with 
thrombin (p<0.05). (D) Western blot analysis of caspase-3 expression in AEC and lung 
fibroblasts. Confluent cultures of AEC (lanes 1 and 2) and lung fibroblasts (lanes 3 and 4) 
were incubated with or without thrombin for 24 hours. Cell were collected with lysis buffer, 
subjected to SDS-polyacrylamide gels, and analyzed by immunoblotting using anti-caspase-
3 antibodies from Cell Signaling Technology. Expression of ǃ-actin is shown to confirm the 
equal loading of protein. Note that caspase-3 antibody recognizes full length pro-caspase-3 
(35kDa) and the fragment (17 kDa) from caspase-3 resulting from cleavage.  
5. Effects of direct thrombin inhibitor dabigatran on aec and lung fibroblasts 
in vitro 
Thrombin is a well-known mitogen and has been shown to induce human lung fibroblast 
proliferation. We measured the effect of dabigatran on thrombin-induced lung fibroblast 
proliferation using a quick cell proliferation assay. This method is based on cleavage of a 
tetrazolium salt, WST-1, to formazan by cellular mitochondrial dehydrogenases. Expansion 
of the number of viable cells results in an increase in the activity of the mitochondrial 
dehydrogenases leading to an increase in the amount of formazan dye detected by 
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spectrometry. Basal levels of viable lung fibroblasts were in a range of between 0.38 and 0.51 
OD. Thrombin increased fibroblast proliferation 1.8-fold within 24 hours. The direct 
thrombin inhibitor, dabigatran, itself had no significant effect on lung fibroblast 
proliferation, yet dabigatran significantly inhibited thrombin-induced proliferation of lung 
fibroblasts. Neither thrombin nor dabigatran affected AEC cell proliferation (Fig. 5A). 
Dabigatran, however, inhibited thrombin-induced apoptosis of AEC A549 (Fig. 5B). 
 
 
Fig. 5. (A) Dabigatran inhibits thrombin-induced lung fibroblasts proliferation and has no 
effects on the proliferation of AEC. (B) Dabigatran inhibits thrombin-induced apoptosis of 
AEC. The asterisk represents statistically significant (p<0.05) differences between cells 
stimulated with thrombin versus cells stimulated with thrombin and dabigatran. 
 
Fig. 6. (A) Dabigatran inhibits ǂ–smooth muscle actin (ǂ–SMA) expression in lung 
fibroblasts. (B) The images were scanned and analyzed with NIH Imaging software. 
Densitometric analysis of immunoblots from 3 independent experiments is presented. The 
asterisk represents statistically significant differences (p<0.05) between cells stimulated with 
thrombin and dabigatran versus cells treated with thrombin alone. 
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The appearance of myofibroblasts in areas of active fibrosis strongly suggests that 
myofibroblasts are key contributors to the pathogenesis of SSc-ILD. Lung fibroblasts from 
SSc-ILD patients express abundant and highly organized ǂ-SMA (Bogatkevich et al., 2001). 
Moreover, thrombin receptor PAR-1 and ǂ-SMA co-localize in lung tissue in early stages of 
lung fibrosis (see Fig. 3). In contrast, normal lung fibroblasts contain relatively small 
amounts of ǂ-SMA which is not fully organized. Previously we reported that within 24 
hours of exposure thrombin increases the amount of highly organized ǂ-SMA in normal 
lung fibroblasts (Bogatkevich et al., 2001 and 2003). Although dabigatran had no effect on 
the basal level of ǂ-SMA in normal lung fibroblasts, dabigatran significantly decreased 
thrombin-induced ǂ-SMA expression in a dose-dependent manner (Fig. 6). 
Contractile phenotype is another characteristic feature of myofibroblasts. Contractile forces 
of the myofibroblast are generated by ǂ-SMA, which is extensively expressed in stress fibers 
and by large fibronexus adhesion complexes connecting intracellular actin with extracellular 
fibronectin fibrils (Gabbiani, 2003). Fibroblasts cultured in collagen gel matrices provide an 
in vitro model of fibrocontractility and fibrosing diseases such as scleroderma and IPF 
(Grinnell, 1999). When cultured within collagen gels fibroblasts recognize collagen fibers 
leading to contraction of the gels. This is believed to reflect the in vivo phenomenon of 
wound contraction and extracellular remodeling in connective tissue. In lung fibrosis it 
might also reflect the pathologic stiffness observed in SSc-ILD and other restrictive lung 
diseases. We previously observed that thrombin induces collagen gel contraction by normal 
lung fibroblasts in a dose-dependent manner with a maximal effect at 0.5 U/ml 
(Bogatkevich et al., 2001). To further investigate the effects of dabigatran on collagen gel 
contraction we used floating and fixed collagen gel assays with normal and SSc lung 
fibroblasts treated with and without thrombin or dabigatran for 48 hours. Contraction of 
floating collagen gels is considered to resemble more closely the initial phase of wound 
contraction and reflects the induction of the myofibroblast phenotype by various growth 
factors (Grinnell, 1999; Shi-Wen et al., 2004). In contrast, attached or fixed collagen gels serve 
as a model of the late phase of excessive scarring observed in contractures and reflect the 
direct ability of proteins to enhance contraction of already formed ǂ-SMA through 
mechanical stress. SSc lung fibroblasts inherently contain higher levels of ǂ-SMA and 
readily contracted both floating and fixed collagen gels (Fig. 7). Dabigatran significantly 
reduced collagen gel contraction by SSc lung fibroblasts and ǂ-SMA in both floating and 
fixed collagen gels; however, thrombin only slightly induced ǂ-SMA and did not 
significantly affect collagen gel contraction by SSc lung fibroblasts.  
We observed notable differences for floating and fixed collagen gels seeded with normal 
lung fibroblasts when stimulated with thrombin. Thrombin strikingly contracted floating 
collagen gels within 48 hours in a similar manner as within 24 hours; in contrast, thrombin 
only slightly affected fixed collagen gels. Similarly, ǂ-SMA was induced to a much higher 
extent by thrombin in floating gels as compared to fixed gels. In contrast, dabigatran 
inhibited collagen gel contraction and ǂ-SMA not only in floating but also in fixed collagen 
gels, thus blocking differentiation to a myofibroblast phenotype, as well as reversing the 
already existing myofibroblast phenotype. 
Normal lung fibroblasts naturally produce collagen type I and CTGF in very low 
concentrations. Thrombin and the PAR-1 selective activating peptide PAR1-AP notably 
increased the production of both of these proteins within 48 hours. Pre-treatment of lung 
fibroblasts with dabigatran (1µg/ml) prevented the accumulation of collagen type I and 
CTGF induced by thrombin, but not by PAR1-AP (Fig. 8A).  
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Fig. 7. (A) Inhibition of floating and fixed collagen gel contraction by dabigatran in lung 
fibroblasts. Data are presented as mean values ± SD of three experiments. The asterisk 
represents statistically significant differences (p<0.05) between cells stimulated with 
thrombin and dabigatran versus cells treated with thrombin alone. (B) ǂ-SMA expression in 
floating and fixed collagen gels 
Lung fibroblasts from SSc-ILD patients express considerably higher levels of ǂ-SMA, CTGF, 
and collagen type I when compared with normal lung fibroblasts. To establish whether 
dabigatran would interfere with the expression of these markers of fibrogenesis, we 
incubated SSc lung fibroblasts with dabigatran (1µg/ml) for 24, 48, 72, and 96 hours. We 
observed that the addition of dabigatran for 72 and 96 hours reduced the levels of ǂ-SMA 
and CTGF; however, treatment of cells with dabigatran for 48 and 24 hours had little or no 
effect (Fig. 8B). In contrast, the level of collagen type I was not significantly affected by 
dabigatran even after 72 hours. Yet after 96 hours of incubation with dabigatran SSc lung 
fibroblasts expressed significantly less collagen type I. To investigate whether, in addition to 
ǂ-SMA expression, ǂ-SMA organization would also be affected by dabigatran in SSc lung 
fibroblasts, we performed fluorescence microscopy studies. We observed that prolonged 
incubation of SSc lung fibroblasts with dabigatran indeed results in decreased ǂ-SMA 
expression and organization (Fig. 8C). Over-production of collagen with increased 
expression of CTGF is considered to be a molecular hallmark of fibrosis (Grotendorst et al., 
2004). Thrombin increases the expression of collagen type I and CTGF (Chambers et al., 1998 
and 2000, Bogatkevich et al., 2006). Importantly, we have demonstrated that dabigatran 
restrains thrombin-induced accumulation of collagen type I and CTGF in human lung 
fibroblasts. Although we observed that incubation of SSc-ILD fibroblasts with dabigatran for 
24 hours had no effect, upon longer exposure to dabigatran (72 hours) considerable 
inhibition of CTGF and ǂ-SMA expression/organization was observed. Even longer 
exposure (96 hours) was required for dabigatran to significantly decrease collagen type I, 
suggesting that down-regulation of collagen by dabigatran in SSc lung fibroblasts occurs 
after inhibition of CTGF and ǂ-SMA. It was reported that CTGF induces collagen I by 
stimulating transcription and promoter activity (Chujo et al., 2005; Gore-Hyer et al., 2002), 
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and diminishing CTGF by small interfering RNA lowers collagens I and IV in rats (Luo et 
al., 2008). Similarly, the inhibition of ǂ-SMA by the NH2-terminal peptide of ǂ-SMA results 
in reduction of collagen gene expression (Hinz et al., 2002). Therefore, our data suggest that 
dabigatran may contribute to collagen type I down-regulation secondarily via reduced 
expression of CTGF and ǂ-SMA. 
 
 
Fig. 8. (A) Dabigatran inhibits thrombin- but not PAR-1-AP-induced collagen type I and 
CTGF. (B) Dabigatran inhibits collagen type I, CTGF, and ǂ–SMA expression in scleroderma 
lung fibroblasts. (C) Dabigatran inhibits ǂ–SMA expression and organization in scleroderma 
lung fibroblasts. The experiments were repeated three times in three different cell lines and 
representative immunoblots and images are presented. 
6. In vivo antifibrotic effects of direct thrombin inhibition with dabigatran 
Since dabigatran restrained important in vitro profibrotic events in lung fibroblasts, we 
reasoned that dabigatran would diminish bleomycin-induced pulmonary fibrosis. For in 
vivo studies we employed dabigatran etexilate, the oral prodrug of dabigatran. The prodrug 
does not have antithrombin activity; however, after oral administration dabigatran etexilate 
is rapidly converted by ubiquitous esterases to the active moiety, dabigatran (Sorbera et al., 
2005, Wienen et al., 2007). Drugs administrated during the early phase of tissue injury act 
predominantly as anti-inflammatory agents and should be considered as “preventive 
treatment”, whereas “true” antifibrotic agents might be effective irrespective of timing, 
particularly if administrated during the “fibrotic” or later phase of the model (Moeller et al., 
2008). To distinguish between anti-inflammatory and antifibrotic drug effects, we compared 
the effect of oral administration of dabigatran etexilate on the day of bleomycin instillation 
(day 1) and on day 8 after bleomycin instillation in mice.  
In control mice that received saline or saline and dabigatran etexilate, lung histology was 
characterized by alveolar structures composed of septa, vascular components, and 
connective tissue. Alveolar septa were thin allowing maximum air to occupy the lung. Lung 
tissue isolated from bleomycin-treated mice demonstrated extensive peribronchial and 
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interstitial infiltrates of inflammatory cells (H&E staining), thickening of the alveolar walls, 
and multiple focal fibrotic lesions with excessive amounts of ECM protein shown by trichrome 
differential staining (Fig. 9A). By contrast, significantly fewer cellular infiltrates, decreased 
thickness of alveolar septa, and reduced accumulation of ECM proteins were all noted in mice 
treated with dabigatran etexilate. Importantly, such beneficial effects of dabigatran etexilate on 
bleomycin-induced pulmonary fibrosis were observed not only in mice receiving dabigatran 
etexilate beginning on the same day as bleomycin (day 1), but were seen also in mice that 
received dabigatran etexilate beginning on day 8 after bleomycin administration (Fig. 9A). The 
overall level of fibrotic changes was quantitatively assessed based on the Ashcroft scoring 
system (Ashcroft et al., 1988). The score in mice treated with bleomycin + placebo was nearly 
9-fold higher compared to control mice (5.76±1.64 and 0.65±0.7 respectively). Fibrosis in mice 
treated with dabigatran etexilate beginning on day 1 after bleomycin instillation was 
significantly reduced (2.8-fold, p < 0.05) when compared to the bleomycin + placebo group, 
suggesting an anti-inflammatory effect of dabigatran (Fig. 9B). 
 
 
Fig. 9. Effect of dabigatran etexilate on bleomycin-induced pulmonary fibrosis. (A) 
Representative histological findings of lung inflammation and fibrosis. 1 – control (saline 
+ placebo or saline + dabigatran), 2 - bleomycin + placebo, 3 – bleomycin + dabigatran 
etexilate (day 1), 4 – bleomycin + dabigatran etexilate (day 8), n = 40 (10 mice per group) 
(B) Quantitative evaluation of fibrotic changes (Ashcroft scores). (C) Collagen lung 
content measured by hydroxyproline assay, n = 32 (8 mice per group). Values are the 
mean ± SD. * = P < 0.05 versus bleomycin + placebo-treated mice. 
Interestingly, fibrosis in mice that received dabigatran beginning on day 8 after bleomycin 
instillation was also significantly reduced (1.9-fold, p < 0.05) compared to the bleomycin + 
placebo group, suggesting that in addition to anti-inflammatory properties dabigatran 
demonstrated a strong anti-fibrotic effect. 
The most profound development of fibrosis in the bleomycin model is observed by day 21; 
therefore, we determined the effect of dabigatran on collagen accumulation in lungs 21 days 
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after bleomycin treatment. To quantify collagen accumulation within the lungs we 
employed hydroxyproline assay, which is based on colorimetric measurements of 
hydroxyproline in lung hydrolysates reflecting total collagen in lung tissue. We observed 
that dabigatran etexilate did not affect the basal level of hydroxyproline (data not shown). 
However, dabigatran etexilate significantly lowered hydroxyproline in bleomycin-treated 
mice by 64% and by 39% when administrated beginning on day 1 and day 8, respectively 
(Fig. 9C). From these studies, we conclude that dabigatran etexilate downregulates lung 
collagen by exerting an antifibrotic effect via thrombin inhibition. 
 
 
Fig. 10. Negative correlation of collagen content in lung tissue versus dabigatran levels in 
plasma on day 1 (Group A) and day 8 (Group B), respectively. 
The association between hydroxyproline levels in lung tissue and dabigatran concentrations 
in plasma was tested using the Spearman rank correlation test. The average plasma 
concentration of dabigatran obtained from mice fed with dabigatran chow was 342.1 ± 90.0 
ng/mL (n=21). We observed a strong negative correlation of hydroxyproline versus 
dabigatran plasma levels (Fig. 10). There was no correlation between hydroxyproline and 
dabigatran plasma levels in control mice receiving saline and dabigatran chow (data not 
shown). This suggests that dabigatran affects collagen expression induced by tissue injury 
(fibrosis) while not interfering with basal levels of collagen in normal lung tissue. 
The total nucleated cell count in BALF was markedly higher in the bleomycin-treated group 
on day 14 as compared to saline control animals (Table 1). 
Bronchoalveolar lavage was performed on day 14 after bleomycin administration. Data are 
presented as mean ± SD (n = 8 mice per treatment group). * = P < 0.01 versus bleomycin + 
placebo-treated mice.  
Dabigatran etexilate treatment starting on day 1 and day 8 significantly reduced total 
nucleated BAL cell counts from bleomycin-treated mice (p < 0.01). Dabigatran etexilate 
alone did not affect BALF cell counts (data not shown). The percentage of BALF neutrophils 
was significantly decreased in bleomycin/dabigatran etexilate-treated mice when compared 
to bleomycin/placebo-treated mice (p < 0.01). Total BALF protein was increased by 7.9-fold 
in bleomycin-placebo treated mice when compared to control and was significantly 
decreased by dabigatran treatment (p < 0.001). On day 21 after bleomycin instillation there 
was notably fewer cells in BALF in mice treated with dabigatran etexilate when compared to 
placebo-treated mice. However, there were no significant differences in cell numbers among 
studied groups (data not shown). 
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Parameters Control Bleo/Placebo Bleo/Dabigatran 
Day 1 
Bleo/Dabigatran 
Day 8 
Total Protein 
(mg/ml) 
0.24±0.09 1.89±0.26 0.87±0.41* 0.89±0.36* 
Total Cell 
(x105/ml) 
8.0±3.5 41.9±17.0 18.2±7.5* 21.0±8.5* 
Macrophages 
(%) 
97.8±1.6 71.6±8.3 84.8±9.3* 79.4±9.0 
Lymphocytes 
(%) 
2.2±1.4 10.3±4.4 8.7±3.7 9.1±5.8 
Neutrophils (%) 0 18.1±5.6 6.5±2.2* 11.5±5.4* 
Table 1. Analysis of bronchoalveolar lavage fluid 
 
 
Fig. 11. Effect of dabigatran etexilate on PDGF-AA (A) and TGF-ǃ1 (B) levels in BALF. (C) 
TGF-ǃ1 expression in lung tissue. 1 – control (saline/placebo), 2 - bleomycin/placebo, 3 – 
bleomycin/dabigatran etexilate (day 1), 4 – bleomycin/dabigatran etexilate (day 8), n = 24 (6 
mice per group). Values are the mean ± SD. * = P < 0.01 versus bleomycin/placebo-treated 
mice. 
We observed that PDGF-AA was up-regulated (11.3-fold) when compared to controls in 
bleomycin-placebo-treated mice. Dabigatran etexilate significantly reduced PDGF-AA by 
65% and 54% when initiated on day 1 and day 8, respectively (p<0.01) (Fig. 11A). The level 
of TGF-ǃ1 in bleomycin-placebo-treated mice was 2.7-fold higher compared to controls 
(saline/placebo- and saline/dabigatran-treated mice). Dabigatran etexilate significantly 
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reduced TGF-ǃ1 concentrations from 54.9±6.1 pg/ml in bleomycin/placebo-treated mice to 
29.9±9.3 and 31.1±8.7 pg/ml when administered beginning on day 1 and day 8, respectively 
(p<0.01, Fig. 11B). TGF-ǃ1 expression was also assessed by immunohistochemistry in lung 
tissue. In this analysis, TGF-ǃ1 was not detectable in lung from control mice, whereas it was 
strongly expressed in fibrotic areas of lung tissue from mice treated with bleomycin plus 
placebo (Fig. 11C). Dabigatran etexilate visibly reduced TGF-ǃ1 expression when used as 
either early or late treatments. Similar to TGF-ǃ1, CTGF and ǂ-SMA were not detectable in 
lung tissue from control mice, with the exception of ǂ-SMA expression in smooth muscle 
cells located in and around blood vessels and airways (Fig. 12). However, CTGF and ǂ-SMA 
were each strongly upregulated in the lungs of bleomycin-treated mice. Dabigatran etexilate 
reduced this expression of CTGF and ǂ-SMA in lung tissue, when administered beginning 
on either day 1 or day 8 of bleomycin treatment.  
 
 
Fig. 12. Immunohistochemical evaluation for CTGF (A) and ǂ-SMA (B) expression in lung 
tissue.  
In this and all other experiments within the study we found that both early and late 
treatments with dabigatran etexilate were able to inhibit bleomycin-induced pulmonary 
fibrosis; however, the inhibition of pulmonary fibrosis was more profound with early 
administration. The efficacy of early treatment with dabigatran etexilate was higher because 
it targeted the inflammatory stage of fibrosis, while later treatment was introduced at the 
time of a more developed degree of lung injury. The role of inflammation in the 
pathogenesis of progressive pulmonary fibrosis remains a controversial issue. Bleomycin 
causes a severe acute inflammatory response followed by chronic inflammation and fibrosis. 
It has been shown that the degree of inflammation in bleomycin-induced lung injury is 
associated with the intensity of fibrosis (Moore & Hogaboam, 2008). 
The concentration of dabigatran etexilate used in these experiments yielded plasma levels 
that are slightly higher than those achieved in patients treated with dabigatran etexilate for 
various thrombotic diseases (~180 ng/ml peak levels achieved with 150 mg twice daily 
dose) (Van Ryn et al., 2010). The dose used in this study resulted in a ~2-fold elevation of the 
aPTT and ~10-fold elevation of the TT (Fig. 13A).  
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Fig. 13. (A) Effect of increasing concentrations of dabigatran on the thrombin time (TT) and 
activated partial thromboplastin time (aPTT) clotting times in mouse plasma in vitro. Data 
expressed as mean of duplicate determinations. (B) Effect of dabigatran etexilate on level of 
active thrombin in BALF. 
Such prolongation in mouse plasma is consistent with findings in human plasma, where it 
has also been shown that change in the TT is more sensitive to dabigatran than is the aPTT. 
Though it is not possible to directly relate plasma levels and/or anticoagulation from mice 
to humans, it is important to note that the antifibrotic effects observed in our studies were 
achieved at plasma levels and pharmacological effects consistent with human dosing.  
It is also important to note that dose of dabigatran etexilate used in this study significantly 
reduced but did not completely inhibit thrombin activity in BALF (Fig. 13B). We did not 
observe any bleeding side-effects during the study suggesting that levels of dabigatran in 
mouse plasma were not sufficient to completely eliminate thrombin from the normal 
hemostatic process. However, such doses of dabigatran etexilate ameliorated lung fibrosis 
even after it had been established, indicating that dabigatran etexilate could safely be 
administered in chronic forms of lung fibrosis, at least in mice. 
7. Conclusions 
Tissue injury with activation of the coagulation cascade and increased thrombin activity 
with deposition of fibrin are characteristic features of pulmonary fibrosis – the end result of 
a heterogeneous group of disorders that includes IPF and SSc-ILD. Characterized by 
microvascular injury and inflammation, SSc-ILD culminates in excessive deposition of 
extracellular matrix proteins, often resulting in severe lung dysfunction and death. 
Although cyclophosphamide treatment may stabilize lung function in some patients, long-
term treatment is required and significant toxicity may occur (Berezne et al., 2007; Strange et 
al., 2008). There is, therefore, a great need for new therapeutic approaches that would be 
more effective and less toxic than current treatments. Dabigatran etexilate represents the 
first synthetic oral, reversible, direct inhibitor of thrombin with a very favorable biochemical 
and pharmacological profile that translates into clinical efficacy and safety in patients with 
or at risk of thrombotic disorders (Stangier, 2008). The current study provides important 
preclinical information about the feasibility and efficacy of dabigatran etexilate for the 
treatment of fibrotic diseases, including IPF and SSc-ILD, in which there is evidence for 
tissue injury with overexpression of thrombin and downstream fibrogenesis. Any future 
studies of thrombin inhibition for the treatment of SSc-ILD would need to demonstrate a 
positive benefit/risk ratio taking into account potential risks such as gastrointestinal tract 
hemorrhage. 
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